Hepatitis B is one of the most critical vaccine-preventable infectious diseases globally. Unlike Hepatitis A, Hepatitis B has a high potential to transition into a lifelong chronic infection, exposing patients to severe liver pathologies including cirrhosis, chronic hepatic failure, and primary hepatocellular carcinoma (HCC). Comprehensive universal screening, timely post-exposure prophylaxis, and widespread active immunization remain the cornerstones of global prevention.
Clinical Practice Rule
Screen Early, Immunize Universally, Act Rapidly: Universal HBsAg screening in every pregnancy, universal infant vaccination, antibody verification in high-risk individuals, and rapid post-exposure HBIG combined with vaccination within 24 hours are paramount to eliminating chronic HBV transmission and liver cancer.
1. Virology & Transmission Pathways
Hepatitis B virus (HBV) is a small, enveloped, double-stranded DNA virus belonging to the Hepadnaviridae family that selectively infects human hepatocytes. Serological diagnosis and disease stratification rely heavily on specific viral antigen markers:
- Hepatitis B Surface Antigen (HBsAg): Present on the outer viral envelope. It serves as the primary diagnostic and screening marker for active (acute or chronic) HBV infection.
- Hepatitis B Core Antigen (HBcAg): Located within the inner nucleocapsid core. It is not detected freely in serum but triggers total anti-HBc and IgM anti-HBc antibody responses.
Transmission & Incubation Characteristics
Unlike Hepatitis A, HBV is not transmitted via the fecal-oral route. Transmission occurs through parenteral or mucosal exposure to infectious blood, semen, vaginal secretions, or saliva. Primary mechanisms include sexual contact, needle sharing, percutaneous occupational injuries, and perinatal exposure. The extended incubation period (average 90 days; range 60–150 days) creates a significant window for silent, asymptomatic transmission.
2. Acute vs. Chronic Infection & Perinatal Risk
The host immune response determines whether acute infection resolves or progresses to chronic carriage:
- Adults: 90–95% of immunocompetent adults clear acute HBV infection naturally, with only 5–10% developing chronic infection.
- Infants & Perinatal Exposure: Age at infection is inversely proportional to chronicity risk. Without preventive intervention, up to 90% of infected infants and 40% of infected young children develop chronic HBV, with 25% ultimately dying of cirrhosis or hepatocellular carcinoma.
Mandatory Prenatal Screening Protocol
All pregnant individuals must undergo serological screening for HBsAg during their first prenatal visit of every pregnancy, regardless of prior vaccination or testing history. Infants born to HBsAg-positive mothers must receive both Hepatitis B Vaccine and Hepatitis B Immune Globulin (HBIG) within 12 hours of birth.
3. High-Risk Populations Requiring Targeted Management
| Category | High-Risk Patient Profiles |
|---|---|
| Sexual & Household Contacts | Sexual partners of HBsAg-positive individuals, men who have sex with men (MSM), individuals with multiple concurrent sex partners, and household family members of chronic carriers. |
| Occupational & Institutional | Healthcare workers, public safety personnel exposed to blood/body fluids, hemodialysis patients, and residents/staff of facilities for individuals with developmental disabilities. |
| Underlying Medical Conditions | Individuals living with HIV, Hepatitis C, chronic liver disease, or diabetes mellitus (due to frequent blood glucose monitoring equipment exposure). |
| Demographic & Exposure Risks | People who inject drugs (PWID), adults born before 1991 (prior to universal childhood vaccination), travelers to or adoptees from endemic regions with high HBV prevalence. |
4. Vaccination Guidelines & Clinical Parameters
The Hepatitis B vaccine is a non-infectious recombinant subunit vaccine containing HBsAg produced in yeast cells. It achieves protective antibody levels in 90–95% of healthy adults and ~98% of full-term infants.
| Clinical Parameter | Evidence-Based Recommendations & Protocols |
|---|---|
| Absolute Contraindication | Severe, immediate anaphylactic reaction to baker’s yeast (Saccharomyces cerevisiae) or any vaccine component. |
| Post-Vaccination Serology (Anti-HBs) | Indicated 1–2 months post-series for high-risk cohorts (healthcare personnel, infants of HBsAg+ mothers, hemodialysis patients, immunocompromised/HIV). Target protective antibody level is Anti-HBs ≥10 mIU/mL. |
| Booster Dose Requirements | Not routinely recommended for immunocompetent individuals with documented response. Hemodialysis patients require annual anti-HBs monitoring, with a booster administered if levels drop below 10 mIU/mL. |
5. Post-Exposure Prophylaxis (PEP) Management
Post-exposure prophylaxis should be initiated as soon as possible following percutaneous, ocular, mucosal, or sexual exposure to blood or body fluids, ideally within 24 hours (and no later than 7 days for percutaneous / 14 days for sexual exposure).
| Exposed Individual Status | Recommended Prophylactic Action Plan | Additional Clinical Workup |
|---|---|---|
| Unvaccinated / Non-Responder | Administer 1 dose of Hepatitis B Immune Globulin (HBIG) immediately + initiate the complete Hepatitis B vaccine series. | Obtain baseline source HBsAg testing and exposed individual baseline serology. |
| Fully Vaccinated (Untested / Low Anti-HBs) | Administer 1 single vaccine booster dose immediately if exposed to a known HBsAg-positive source. | Re-test Anti-HBs in 1–2 months if non-responder history is suspected. |
| Partially Vaccinated | Administer HBIG if source is HBsAg-positive, and complete the remaining doses of the primary vaccine series. | Assess for concurrent bloodborne exposures (HIV, HCV, HAV). |
Clinical Practice Pearls
- Yeast Allergy Safety Check: Always screen for severe baker’s yeast anaphylaxis prior to administering recombinant Hepatitis B vaccines.
- Bloodborne Co-Exposure Rule: Any significant parenteral blood exposure warranting HBV prophylaxis must trigger concurrent evaluation and baseline testing for HIV, Hepatitis C, and Hepatitis A.
- Primary Screening Marker: HBsAg is the pivotal initial screening test; its persistence beyond 6 months formally defines chronic Hepatitis B infection.
